Fundraising Fox
Novopyxis
Cambridge, US · Founded 2013 · Delaware corporation · 1 known investors
Find your way into Novopyxis
Sign up to find every way you can get introduced to Novopyxis
- Your email: who you already know at Novopyxis, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Novopyxis team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
NovoPyxis applies mathematics and physics principles, including knot theory and fluid dynamics, to drug design and delivery, predicting protein structures of uncrystallized targets and designing peptide agonists. Its work includes a cardiomyopathy drug candidate and a transdermal device for delivering large-molecule drugs into skin.
Founders & leadership
Investors · 1
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$855.9K disclosed across 2 rounds · 2014–2017
▶$512.9KraisedJul 2017 · 19 investors · BiotechnologyRule 506(b)
- Daniel VannoniDirector
- Raja SrinivasDirector
- Madhavi GaviniExecutive Officer, Director
- Offering amount
- $512.9K
- Amount sold
- $512.9K
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$343KraisedJul 2014 · 12 investors · Biotechnology
- Raja SrinivasDirector
- Madhavi GaviniExecutive Officer, Director
- Daniel VannoniExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $343K
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 04
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Novopyxis went on to found or lead other companies.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $496.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Novopyxis do?
- NovoPyxis applies mathematics and physics principles, including knot theory and fluid dynamics, to drug design and delivery, predicting protein structures of uncrystallized targets and designing peptide agonists. Its work includes a cardiomyopathy drug candidate and a transdermal device for delivering large-molecule drugs into skin.
- Who are Novopyxis's investors?
- Novopyxis's investors include Bantam Group.
- How much funding has Novopyxis raised?
- Novopyxis has disclosed $855.9K raised across 2 rounds.
- Where is Novopyxis headquartered?
- Novopyxis is headquartered in Cambridge, US.